Skip to main content

Luminex Stock Drops 8 Percent Despite Strong Q3 Revenues

NEW YORK, Oct. 25 (GenomeWeb News) - Shares in Luminex were down 8 percent, or $.88, at $10.06 in mid-afternoon trading even though the company today reported increased revenues for the third quarter.

 

As GenomeWeb News reported today, Luminex had a 28.7-percent increase in third-quarter revenues from last year's third quarter revenues. The company noted a significant narrowing in losses.

 

The company noted an increase in R&D investment drove the increase.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.